Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG.

Nat Med. 2016 Aug;22(8):851-60. doi: 10.1038/nm.4123. Epub 2016 Jul 4.

PMID:
27376576
2.

Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis.

Ruhland MK, Loza AJ, Capietto AH, Luo X, Knolhoff BL, Flanagan KC, Belt BA, Alspach E, Leahy K, Luo J, Schaffer A, Edwards JR, Longmore G, Faccio R, DeNardo DG, Stewart SA.

Nat Commun. 2016 Jun 8;7:11762. doi: 10.1038/ncomms11762.

3.

The Action of Discoidin Domain Receptor 2 in Basal Tumor Cells and Stromal Cancer-Associated Fibroblasts Is Critical for Breast Cancer Metastasis.

Corsa CA, Brenot A, Grither WR, Van Hove S, Loza AJ, Zhang K, Ponik SM, Liu Y, DeNardo DG, Eliceiri KW, Keely PJ, Longmore GD.

Cell Rep. 2016 Jun 14;15(11):2510-23. doi: 10.1016/j.celrep.2016.05.033. Epub 2016 Jun 2.

4.

Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.

Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG.

Oncotarget. 2016 May 22. doi: 10.18632/oncotarget.9551. [Epub ahead of print]

5.

Antagonizing Integrin β3 Increases Immunosuppression in Cancer.

Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, Fox GC, Kobayashi T, Steri V, Roomp K, Fontana F, Hurchla MA, Knolhoff BL, Meyer MA, Morgan EA, Tomasson JC, Novack JS, Zou W, Faccio R, Novack DV, Robinson SD, Teitelbaum SL, DeNardo DG, Schneider JG, Weilbaecher KN.

Cancer Res. 2016 Jun 15;76(12):3484-95. doi: 10.1158/0008-5472.CAN-15-2663. Epub 2016 May 23.

PMID:
27216180
6.

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC.

Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4.

PMID:
27055731
7.

Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer.

D'Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B, Bumpass DB, Meyer M, Su X, Wang-Gillam A, Weilbaecher K, Stewart SA, DeNardo DG, Faccio R.

J Exp Med. 2016 May 2;213(5):827-40. doi: 10.1084/jem.20150950. Epub 2016 Apr 4.

PMID:
27045006
8.

Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis.

Demehri S, Cunningham TJ, Manivasagam S, Ngo KH, Moradi Tuchayi S, Reddy R, Meyers MA, DeNardo DG, Yokoyama WM.

J Clin Invest. 2016 Apr 1;126(4):1458-70. doi: 10.1172/JCI83724. Epub 2016 Feb 29.

9.

Regramming myeloid responses to improve cancer immunotherapy.

Zhu Y, Hawkins WG, DeNardo DG.

Oncoimmunology. 2015 May 22;4(6):e974399. eCollection 2015 Jun.

10.

TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy.

Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM.

Cancer Immunol Res. 2015 May;3(5):518-25. doi: 10.1158/2326-6066.CIR-14-0232. Epub 2015 Feb 25.

11.

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG.

Cancer Res. 2014 Sep 15;74(18):5057-69. doi: 10.1158/0008-5472.CAN-13-3723. Epub 2014 Jul 31.

12.

Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer.

Panni RZ, Sanford DE, Belt BA, Mitchem JB, Worley LA, Goetz BD, Mukherjee P, Wang-Gillam A, Link DC, Denardo DG, Goedegebuure SP, Linehan DC.

Cancer Immunol Immunother. 2014 May;63(5):513-28. doi: 10.1007/s00262-014-1527-x. Epub 2014 Mar 21.

13.

A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma.

Sanford DE, Porembka MR, Panni RZ, Mitchem JB, Belt BA, Plambeck-Suess SM, Lin G, Denardo DG, Fields RC, Hawkins WG, Strasberg SM, Lockhart AC, Wang-Gillam A, Goedegebuure SP, Linehan DC.

J Cancer Ther. 2013 May;4(3):797-803.

14.

Targeting tumor-infiltrating macrophages to combat cancer.

Panni RZ, Linehan DC, DeNardo DG.

Immunotherapy. 2013 Oct;5(10):1075-87. doi: 10.2217/imt.13.102. Review.

15.

Cathepsin C is a tissue-specific regulator of squamous carcinogenesis.

Ruffell B, Affara NI, Cottone L, Junankar S, Johansson M, DeNardo DG, Korets L, Reinheckel T, Sloane BF, Bogyo M, Coussens LM.

Genes Dev. 2013 Oct 1;27(19):2086-98. doi: 10.1101/gad.224899.113. Epub 2013 Sep 24.

16.

Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.

Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD, Wang-Gillam A, Eberlein TJ, Denardo DG, Goedegebuure SP, Linehan DC.

Clin Cancer Res. 2013 Jul 1;19(13):3404-15. doi: 10.1158/1078-0432.CCR-13-0525. Epub 2013 May 7.

17.

Tumor-infiltrating macrophages, cancer stem cells and therapeutic responses.

Panni RZ, Linehan DC, Denardo DG.

Oncotarget. 2012 Dec;3(12):1497-8. No abstract available.

18.

Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG.

Cancer Res. 2013 Feb 1;73(3):1128-41. doi: 10.1158/0008-5472.CAN-12-2731. Epub 2012 Dec 5.

19.

Battle over CCL2 for control of the metastatic niche: neutrophils versus monocytes.

Mitchem JB, DeNardo DG.

Breast Cancer Res. 2012 Jul 19;14(4):315. doi: 10.1186/bcr3149.

20.

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM.

Cancer Discov. 2011 Jun;1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028. Epub 2011 Jun 1.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk